OTCMKTS:IPSEY Ipsen - IPSEY Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Ipsen S.A. Please log in to your account or sign up in order to add this asset to your watchlist. $26.50 +0.64 (+2.47%) (As of 02/6/2023 05:33 PM ET) Add Compare Share Share Today's Range$25.91▼$26.5050-Day Range$25.34▼$28.9352-Week Range$21.17▼$32.51Volume543 shsAverage Volume746 shsMarket CapitalizationN/AP/E RatioN/ADividend Yield0.92%Price Target$106.00 ProfileAnalyst RatingsChartCompetitorsDividendHeadlinesShort Interest About Ipsen (OTCMKTS:IPSEY) StockIpsen SA manufactures pharmaceutical products for oncology, neuroscience and rare diseases. It operates through following segments: Specialty Care and Consumer Healthcare. The Specialty Care segment focuses on Oncology with Somatuline, a somatostatin analog for the treatment of neuroendocrine tumors; Cabometyx, the single-agent treatment with significant improvement across all key efficacy endpoints in second-line renal cell carcinoma; Onivyde, a differentiated product with overall survival benefit addressing a high unmet medical need in pancreatic cancer; and Decapeptyl, an established and growing product in Europe and China for prostate cancer and Rare Diseases with Nutropin, a liquid formulation of recombinant human growth hormone and Increlex, a recombinant insulin-like growth factor of human origin. The Consumer Healthcare segment include brands such as Smecta, a naturally extracted purified clay for the symptomatic treatment of acute diarrhea; Tanakan, a standardized extract from the leaves of Ginkgo biloba for the treatment of various neurological and neuro-sens or ial disorders; Forlax, an osmotic laxative indicated for the symptomatic treatment of constipation in adults anRead More Receive IPSEY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ipsen and its competitors with MarketBeat's FREE daily newsletter. Email Address IPSEY Stock News HeadlinesJanuary 27, 2023 | markets.businessinsider.comIpsen: CHMP Recommends Not To Grant Marketing Authorization For Palovarotene As Treatment For FOPJanuary 27, 2023 | msn.comIpsen faces another setback for bone disorder drug with EMA panel's rejectionFebruary 6, 2023 | Investing Trends (Ad)"TAKE THAT, CHINA!" USA Gains in EV Battery Arms RaceDid you know each electric car battery requires 220 pounds of graphite – more than lithium, copper, or aluminum? China enjoyed a "near monopoly" in this vital ingredient... until the U.S. made a blockbuster announcement. Now one little-known company is set to play a crucial role in the booming $7 trillion EV revolution. January 27, 2023 | finance.yahoo.comIpsen Receives CHMP Negative Opinion for Palovarotene as a Treatment for Fibrodysplasia Ossificans Progressiva in E.U.January 20, 2023 | msn.comIpsen presents full data showing 'survival benefit' in pancreatic cancer in phase 3 trialJanuary 20, 2023 | finance.yahoo.comIpsen Presents Phase III NAPOLI 3 Trial of Onivyde® Regimen Demonstrating Positive Survival Results in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma at ASCO GIJanuary 20, 2023 | msn.comPublic see pharma workers as Covid heroes, Ipsen survey findsJanuary 13, 2023 | realmoney.thestreet.com3 Potential Biotech Buyout TargetsFebruary 6, 2023 | Wall Street Watch Dogs (Ad)A gold storm is coming…“We are in the early stages of a mania – the calm before the storm.”...January 10, 2023 | bizjournals.comIpsen to buy liver disease drugmaker for $952MJanuary 9, 2023 | benzinga.comSHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Albireo (ALBO)January 9, 2023 | msn.comAlbireo stock jumps 85% as Ipsen set to acquire it for ~$952MDecember 27, 2022 | msn.comIpsen says FDA rejected treatment for rare bone disorderDecember 23, 2022 | au.finance.yahoo.comIpsen receives Complete Response Letter for palovarotene, an investigational treatment for fibrodysplasia ossificans progressivaDecember 8, 2022 | finance.yahoo.comIpsen Provides Update On Phase III CONTACT-01 Trial Evaluating Cabozantinib in Combination With Atezolizumab in Patients With Metastatic Non-small Cell Lung Cancer Previously Treated With Immunotherapy and ChemotherapyDecember 7, 2022 | technews.tmcnet.comEllucian's CEO Laura Ipsen Highlighted in Top 50 Women Leaders in SaaS ListNovember 9, 2022 | seekingalpha.comMerrimack jumps 183% as partner Ipsen says pancreatic cancer trial met main goalNovember 9, 2022 | seekingalpha.comIpsen Onivyde combo meets trial's survival goal in untreated pancreatic cancer patientsOctober 27, 2022 | finance.yahoo.comIpsen Delivers Strong Sales Growth in the First Nine Months of 2022 and Confirms Its Full-year GuidanceOctober 25, 2022 | markets.businessinsider.comIpsen : FDA Postpones Palovarotene Advisory Committee MeetingSeptember 24, 2022 | msn.comIpsen set to invest extra €15m in DublinSeptember 6, 2022 | apnews.comIRLAB’s partner Ipsen Initiates Clinical Studies in Line with Mesdopetam’s Development PlanAugust 12, 2022 | finance.yahoo.comIpsen Completes Acquisition of Epizyme Expanding Its Portfolio in OncologyAugust 5, 2022 | finance.yahoo.comIpsen Extends Expiration Date of Tender Offer for Epizyme, Inc. to 11 August 2022August 3, 2022 | finance.yahoo.comMerrimack Pharma-Ipsen's Cancer Drug Fails In Overall Survival MeasureAugust 3, 2022 | markets.businessinsider.comIpsen: Phase III RESILIENT Trial Evaluating Onivyde Fails To Meet Primary EndpointAugust 3, 2022 | seekingalpha.comIpsen Onivyde fails to improve overall survival of lung cancer patients in phase 3 trialSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive IPSEY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ipsen and its competitors with MarketBeat's FREE daily newsletter. Email Address IPSEY Company Calendar Today2/06/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry Diagnostic substances Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:IPSEY CUSIPN/A CIKN/A Webwww.ipsen.com Phone(315) 833-5000Fax33-01-58-33-50-01Employees5,700Year FoundedN/APrice Target and Rating Average Stock Price Forecast$106.00 High Stock Price Forecast$142.00 Low Stock Price Forecast$86.00 Forecasted Upside/Downside+300.0%Consensus RatingHold Rating Score (0-4)2.08 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio1.88 Quick Ratio1.75 Sales & Book Value Annual Sales$3.55 billion Price / SalesN/A Cash Flow$3.60 per share Price / Cash Flow7.37 Book Value$9.72 per share Price / Book2.73Miscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta0.98 Key ExecutivesDavid G. LoewChief Executive Officer & DirectorAymeric Le ChatelierChief Financial Officer & Executive Vice PresidentAidan MurphyExecutive Vice President-Technical OperationsHoward MayerExecutive Vice President-Research & DevelopmentSteven HildemannChief Medical Officer & Executive Vice PresidentKey CompetitorsBG MedicineOTCMKTS:BGMDFluoroPharma MedicalOTCMKTS:FPMIHemagen DiagnosticsOTCMKTS:HMGNResponse GeneticsOTCMKTS:RGDXQ[email protected] TechnologyOTCMKTS:LPTCView All Competitors IPSEY Stock - Frequently Asked Questions Should I buy or sell Ipsen stock right now? 13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ipsen in the last year. There are currently 2 sell ratings, 8 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" IPSEY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IPSEY, but not buy additional shares or sell existing shares. View IPSEY analyst ratings or view top-rated stocks. What is Ipsen's stock price forecast for 2023? 13 brokerages have issued twelve-month target prices for Ipsen's stock. Their IPSEY share price forecasts range from $86.00 to $142.00. On average, they predict the company's stock price to reach $106.00 in the next year. This suggests a possible upside of 309.9% from the stock's current price. View analysts price targets for IPSEY or view top-rated stocks among Wall Street analysts. How have IPSEY shares performed in 2023? Ipsen's stock was trading at $26.88 on January 1st, 2023. Since then, IPSEY shares have decreased by 3.8% and is now trading at $25.86. View the best growth stocks for 2023 here. Are investors shorting Ipsen? Ipsen saw a increase in short interest in December. As of December 30th, there was short interest totaling 1,000 shares, an increase of 150.0% from the December 15th total of 400 shares. Based on an average daily trading volume, of 2,000 shares, the days-to-cover ratio is presently 0.5 days. View Ipsen's Short Interest. How often does Ipsen pay dividends? What is the dividend yield for Ipsen? Ipsen announced a dividend on Friday, May 27th. Investors of record on Wednesday, June 1st will be paid a dividend of $0.2269 per share on Thursday, June 9th. This represents a dividend yield of 0.88%. The ex-dividend date is Tuesday, May 31st. Read our dividend analysis for IPSEY. Is Ipsen a good dividend stock? Ipsen (OTCMKTS:IPSEY) pays an annual dividend of $0.24 per share and currently has a dividend yield of 0.92%. Read our dividend analysis for IPSEY. What is Ipsen's stock symbol? Ipsen trades on the OTCMKTS under the ticker symbol "IPSEY." How do I buy shares of Ipsen? Shares of IPSEY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Ipsen's stock price today? One share of IPSEY stock can currently be purchased for approximately $25.86. How many employees does Ipsen have? The company employs 5,700 workers across the globe. How can I contact Ipsen? Ipsen's mailing address is 65 quai Georges Gorse, Boulogne-Billancourt cedex I0, 92650. The official website for the company is www.ipsen.com. The company can be reached via phone at (315) 833-5000, via email at investor.relations@ipsen.com, or via fax at 33-01-58-33-50-01. This page (OTCMKTS:IPSEY) was last updated on 2/6/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.